Skip to main content

Table 1 General characteristics of the different treatment groups

From: Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure

 

Standard medical therapy (n = 6)

Molecular adsorbent recirculating system + standard medical therapy (n = 6)

Prometheus + standard medical therapy (n = 6)

P value

Age (years)

55.8 ± 1.9

54.5 ± 3.0

43.2 ± 4.7

0.097

Sex (male/female)

3/3

5/1

4/2

0.585

Serum bilirubin (mg%)

29.9 ± 4.5

25.6 ± 3.6

34.3 ± 1.9

0.245

Prothrombin time

37.6 ± 2.9

39.8 ± 4.0

40.9 ± 7.0

0.888

Albumin (g/l)

26.3 ± 1.7

27.8 ± 0.8

29.4 ± 1.7

0.348

Creatinin (mg%)

1.5 ± 0.3

1.6 ± 0.5

1.5 ± 0.2

0.984

Hepatic encephalopathy score

1 ± 0.4

1.5 ± 0.2

1.2 ± 0.4

0.473

Hepatic venous pressure gradient (mmHg)

16.8 ± 1.4

19.2 ± 1.0

15.5 ± 2.5

0.245

Child-Pugh score

13 ± 0.4

12.7 ± 0.3

11.8 ± 0.3

0.070

Sequential Organ Failure Assessment score

9.3 ± 0.9

8.3 ± 0.8

9.2 ± 0.7

0.637

Model for End-stage Liver Disease score

24.3 ± 2.4

22.7 ± 2.2

29.7 ± 1.7

0.081

Maddrey's discriminant function

70.5 ± 10.5

55.6 ± 7.3

63.2 ± 18.1

0.501

  1. Data presented as the mean ± standard error of the mean, and represent values of the day before start of study.